Tag: shows

 

Organised ‘overkill’: China shows off rapid lockdown system after latest outbreak

BEIJING (Reuters) – Days after a 17-year-old girl tested positive for COVID-19 in a remote part of western China last week, health authorities said they had tested over 4.7 million people in the region.

FILE PHOTO: Chinese Foreign Ministry spokesman Wang Wenbin speaks during a news conference in Beijing, China July 27, 2020. REUTERS/Tingshu Wang

China’s strict formula of immediate lockdowns and mass testing even at the first signs of infection has been vital to its success in controlling the disease, allowing its economy to quickly recover from the crisis, officials say.

The highly orchestrated strategy – described as “overkill” even by its own proponents – is unique among major economies at a time when Europe and the United States are facing a massive surge of new cases and often chaotic policies.

At the time the girl was diagnosed, the Kashgar region of Xinjiang had reported no new cases for almost 70 days.

“China has taken the most comprehensive, strictest and most thorough control and prevention measures since the COVID-19 pandemic started,” foreign ministry spokesman Wang Wenbin said on Wednesday.

“The facts show China’s measures are effective.”

Key to the programme are factors unique to China, including the Communist Party’s tight grip on all aspects of society.

Authorities have unimpeded access to personal information as part of an expansive surveillance network, which has played a major role in tracing infections.

The government has also quickly enlisted the help of businesses, which are churning out tens of millions of test kits, and tightly controls their pricing and distribution, issues which have severely set back efforts to contain the disease in other countries.

China has reported just 2,382 cases since June. By contrast, Germany and France are set to follow Italy and Spain back into partial lockdowns, as Europe reported a record 230,000 cases in one day earlier this week, while U.S. cases are set to hit 9 million soon.

MASS TESTINGS

In August, Beijing ordered all major hospitals in the country to offer testing, and said there should be one urban testing base constructed for every million residents, with the capacity to scale up to 30,000 tests a day in a local outbreak.

Regions are also required to share resources, in sharp contrast to the early days of the outbreak, when several cities were accused of stealing equipment from each other.

The system, like all Chinese Communist blueprints, is highly structured around specific targets; testing teams should be able to complete a campaign within seven days.

Earlier this month, almost 11 million test results were delivered in around five days in the eastern port city of Qingdao. In Wuhan, the initial epicentre of the pandemic, over 9 million samples were taken over 10 days in May.

The mass testings are mandatory. Some are held in outdoor sporting venues and city parks, with hundreds of people lining up.

PUTTING PEOPLE AT EASE

Epidemiologists have called into question the efficacy of the mass testing events, noting some patients require multiple tests over time

Love Island’s Jack Fincham shows off fitness transformation

Jack Fincham showed off his abs (Picture: Jack Fincham/Rex)

Love Island star Jack Fincham looks a little unrecognisable in a new snap which sees him showing off his incredible fitness transformation.

The reality star’s hard work has clearly been paying off, as he showed off his abs in a mirror selfie.

Sharing a photo of his epic transformation, he wrote in the caption: ‘Dad bod.’

His friends and fans were quick to cheer him on, with fellow Love Island star and new dad Jamie Jewitt writing: ‘There he is, fighting fit mate 💪’.

Fitness influencer Jacqueline West added: Well done for the discipline Jack! Good luck,’ while former Love Islander Dom Lever simply told him: ‘I would.’

Good to know, Dom. Good to know.

Jack, 29, became a dad for the first time in January this year, welcoming his daughter Blossom with his friend Casey Ranger.

The reality star has since explained that he chose to keep his baby news quiet at first to give Blossom’s mum, who isn’t in the public eye, as ‘peaceful’ a pregnancy as possible.

Jack rose to fame on the fourth series of Love Island (Picture: ITV/REX)

Opening up on his reaction to finding out he was going to be a father, Jack admitted that the first thing he did was panic.

Speaking to The Sun in February, Jack confessed: ‘I’m not going to sit here and lie, at the start, I couldn’t get my head around it at all. I was like, “Sh*t, oh god!”

More: Love Island

‘I just wasn’t expecting it. I remember I was sitting in this bar and I panicked… you just don’t plan for it.’

Jack shot to fame on the fourth series of Love Island back in 2018, where he won the ITV2 dating show with his ex-girlfriend Dani Dyer.

Got a story?

If you’ve got a celebrity story, video or pictures get in touch with the Metro.co.uk entertainment team by emailing us celebtips@metro.co.uk, calling 020 3615 2145 or by visiting our Submit Stuff page – we’d love to hear from you.

MORE: Jack Fincham’s ex claims Love Island star has seen daughter only ‘three times in eight months’

MORE: Jack Fincham ‘devastated’ after crashing his new £35k Mercedes two months after car accident

window.fbApi = (function () {

var fbApiInit = false; var awaitingReady = [];

var notifyQ = function () { var i = 0, l = awaitingReady.length; for (i = 0; i < l; i++) { awaitingReady[i](); } }; var ready = function (cb) { if (fbApiInit) { cb(); } else { awaitingReady.push(cb); } }; var checkLoaded = function () { return fbApiInit; }; window.fbAsyncInit = function () { FB.init({ appId: '176908729004638', xfbml: true, version: 'v2.10' }); fbApiInit = true; notifyQ(); }; return { 'ready' : ready, 'loaded' : checkLoaded }; })(); (function () { function injectFBSDK() { if ( window.fbApi && window.fbApi.loaded() ) return; var d = document, s = 'script', id = 'facebook-jssdk'; var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) { return; } js = d.createElement(s); js.id = id; js.async = true; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); } if ('object' === typeof metro) { window.addEventListener('metro:scroll', injectFBSDK, {once: true}); } else { window.addEventListener('DOMContentLoaded', injectFBSDK, {once: true}); } })();

Source Article

Study in Nature Medicine shows superior patient outcomes in LLS’s Beat AML clinical trial

Rye Brook, NY (Monday, October 26, 2020) – Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.

The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival.

In other key findings, the study demonstrated a paradigm shift in how patients diagnosed with AML should be treated, proving that using genetic information to match patients to targeted therapies leads to better survival rates than the traditional one-size-fits all treatment approach.

AML is an extremely fast-moving cancer of the marrow and blood, affecting 21,000 people in the U.S. a year, and killing 10,000. For decades patients have been given the same treatments almost immediately upon diagnosis because waiting allows the cancer cells to grow out of control. This standard of care involves either infusion of a combination of two chemotherapies, cytarabine and daunorubicin, or treatment with a so-called hypomethylating agent, a drug that unleashes signals allowing the cancer cells to die.

“The study shows that delaying treatment up to seven days is feasible and safe, and that patients who opted for the precision medicine approach experienced a lower early death rate and superior overall survival compared to patients who opted for standard of care,” said John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research of The Ohio State University, and one of the Beat AML leads and corresponding author of the study. “This patient-centric study shows that we can move away from chemotherapy treatment for patients who won’t respond or can’t withstand the harsh effects of the same chemotherapies we’ve been using for 40 years and match them with a treatment better suited for their individual case.”

Going on the Offensive Against AML


Recognizing the urgent need to do better for AML patients, LLS launched this clinical trial in fall 2016 to test multiple novel targeted therapies at major cancer centers across the U.S., in newly diagnosed AML patients aged 60 and older. In a historic first for cancer clinical trials, LLS is the first non-profit health organization to sponsor a trial and hold the IND (Investigational New Drug) application from the U.S. Food and Drug Administration. Beat AML partnered with Foundation Medicine Inc. to employ next generation genomic sequencing to rapidly analyze the patients’ cancer cells, and identify the patients’ AML subtype so they can be given a targeted therapy within a safe timeframe.

“The breadth of this collaboration, with every clinician, cancer center, pharmaceutical partner and all of the many operations and technical support companies, all unified in working toward the common goal of building a new model for tackling this challenging

Coronavirus live updates: COVID-19 positivity rates rising in 37 US states, analysis shows

The number of new cases of COVID-19 recorded across the United States has increased substantially, as has the number of new deaths from the disease, according to an internal memo from the U.S. Department of Health and Human Services that was obtained by ABC News on Monday night.

The memo, which is circulated among the highest levels of the federal government and is used to determine daily priorities for the agencies working on a COVID-19 response, said 40 U.S. states and territories are in an upward trajectory of new infections, while nine jurisdictions are at a plateau and seven others are in a downward trend.

There were 488,498 new cases confirmed during the period of Oct. 19-25, a 26% increase from the previous week. There were also 5,615 fatalities from COVID-19 recorded during the same period, a 15.1% increase compared with the week prior, according to the memo.

The national positivity rate for COVID-19 tests increased from 5.6% to 6.1% in week-to-week comparisons. Meanwhile, 22% of hospitals across the country have intensive care units that are more than 80% occupied. That figure is up from the summertime peak, when 17-18% of U.S. hospitals had 80% of ICU beds full, the memo said.

Arizona reported 848 COVID-19 hospitalizations on Oct. 21, its highest count since Aug. 26, according to the memo.

In the U.S. territory of Guam, which continues to be classified as a “red zone” for COVID-19 infections, an average of 89.7% of inpatient beds and 80.2% of ICU beds were occupied in the week ending Oct. 20, the memo said.

North Dakota saw a record high of 1,036 new cases on Oct. 20, surpassing the 1,000 mark of daily incident cases for the first time, according to the memo.

New Jersey reported 852 daily COVID-19 hospitalizations on Oct. 22, its highest since late July, the memo said.

Oklahoma reached a record 956 COVID-19 hospitalizations on Oct. 22. The previous record was set just two days earlier, according to the memo.

Utah reported an all-time high of 314 COVID-19 hospitalizations on Oct. 21, as several hospitals in the state reached capacity, the memo said.

ABC News’ Josh Margolin contributed to this report.

Source Article

Cold temperatures, vitamin A can help the body burn more fat, study shows

People looking to lose weight may start embracing the winter months after a new study found cold temperatures and increased vitamin A encourage fat burning.

The study, which was published in the journal Molecular Metabolism last week, explored the effects cold temperatures and vitamin A had on converting white fat, which is where excess calories are stored, to brown fat, which “stimulates fat burning and heat generation.”

More than 90% of the human body’s fat deposits are white fat, which is stored in the abdomen, bottom and upper thighs, the study shares.

Cold temperatures applied to mice was found to increase vitamin A production, which resulted in higher fat burning. 

Cold temperatures applied to mice was found to increase vitamin A production, which resulted in higher fat burning. 
(iStock)

LONDON MARATHON MEDALIST SARA HALL SAYS POSITIVITY AND FAITH HELPED HER ACROSS THE FINISH LINE

According to the findings, cold temperatures increased vitamin A levels, which helps convert white to brown fat, thus stimulating fat burning. Vitamin A reserves are mostly stored in the liver. Once cold was applied to the mice in the study, the increases in “the levels of vitamin A and its blood transporter, retinol-binding protein” led to a higher rate of fat burning as the white fat converted to brown as the body attempting to keep itself warm.

Alternatively, when “the vitamin A transporter ‘retinol-binding protein’” was blocked in mice, the fat did not “brown” and the mice were unable to protect themselves from the cold.

FITNESS INFLUENCER SHOWS HOW ‘BEFORE AND AFTER’ PHOTOS ARE MANIPULATED

The study is promising in finding solutions to dealing with weight gain and obesity. Though the study’s lead researcher, Florian Kiefer from the Medical University of Vienna, cautioned against taking large quantities of vitamin A supplements in an effort to lose weight.

WOMAN LOSES 117 POUNDS AFTER BEING TURNED AWAY FROM BRIDAL BOUTIQUE

“Our results show that vitamin A plays an important role in the function of adipose tissue and affects global energy metabolism. However, this is not an argument for consuming large amounts of vitamin A supplements if not prescribed, because it is critical that vitamin A is transported to the right cells at the right time,” explains the MedUni Vienna researcher. “We have discovered a new mechanism by which vitamin A regulates lipid combustion and heat generation in cold conditions. This could help us to develop new therapeutic interventions that exploit this specific mechanism.”

Source Article

Study in Nature Medicine Shows Superior Outcomes for Patients in The Leukemia & Lymphoma Society’s Paradigm-Shifting Beat AML Clinical Trial

RYE BROOK, N.Y., Oct. 26, 2020 /PRNewswire/ — Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.


Leukemia & Lymphoma Society logo (PRNewsfoto/The Leukemia & Lymphoma Society)

The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival.

In other key findings, the study demonstrated a paradigm shift in how patients diagnosed with AML should be treated, proving that using genetic information to match patients to targeted therapies leads to better survival rates than the traditional one-size-fits all treatment approach.

AML is an extremely fast-moving cancer of the marrow and blood, affecting 21,000 people in the U.S. a year, and killing 10,000. For decades patients have been given the same treatments almost immediately upon diagnosis because waiting allows the cancer cells to grow out of control. This standard of care involves either infusion of a combination of two chemotherapies, cytarabine and daunorubicin, or treatment with a so-called hypomethylating agent, a drug that unleashes signals allowing the cancer cells to die.

“The study shows that delaying treatment up to seven days is feasible and safe, and that patients who opted for the precision medicine approach experienced a lower early death rate and superior overall survival compared to patients who opted for standard of care,” said John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research of The Ohio State University, and one of the Beat AML leads and corresponding author of the study. “This patient-centric study shows that we can move away from chemotherapy treatment for patients who won’t respond or can’t withstand the harsh effects of the same chemotherapies we’ve been using for 40 years and match them with a treatment better suited for their individual case.”

Going on the Offensive Against AML

Recognizing the urgent need to do better for AML patients, LLS launched this clinical trial in fall 2016 to test multiple novel targeted therapies at major cancer centers across the U.S., in newly diagnosed AML patients aged 60 and older. In a historic first for cancer clinical trials, LLS is the first non-profit health organization to sponsor a trial and hold the IND (Investigational New Drug) application from the U.S. Food and Drug Administration. Beat AML partnered with Foundation Medicine Inc. to employ next generation genomic sequencing to rapidly analyze the patients’ cancer cells, and identify the patients’ AML subtype so they can be given a targeted therapy within a safe timeframe.

“The breadth of this collaboration, with every clinician, cancer center, pharmaceutical partner and all of the many operations and technical support companies, all unified in working toward the common goal of building a new model for tackling

Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today two patients have demonstrated noticeable signs of improvement following treatment with leronlimab (PRO 140) in helping their recovery from stroke.

The most recent stroke patient, a physician in Mississippi, requested leronlimab, which was administered to him under Mississippi’s recently expanded “Right to Try” statute. The physician’s son, commenting on his father, stated, “He is doing good. Yesterday, he received his second treatment. He said he has been feeling better, and he thinks it is working. He said parts of his body and face that have been numb are starting to change/wake up.”

Scott A. Kelly, M.D., CytoDyn Chairman of the Board, Chief Medical Officer and Head of Business Development, commented, “We are encouraged by leronlimab’s potential to help patients recover from stroke and traumatic brain injury. Independent research has concluded CCR5 is upregulated in neurons after stroke, blocking CCR5 induces motor recovery after stroke, and CCR5 antagonism may enhance learning, memory, and plasticity. CCR5 is rapidly becoming an important target for neural repair in stroke and traumatic brain injury. Our recent data that leronlimab crosses the blood-brain barrier with 70-75% receptor occupancy of the CCR5 receptors in the brain (Macaque model) is encouraging for the potential to enhance recovery in stroke and traumatic brain injury and explore a variety of central nervous system pathology.”

A second stroke patient was receiving treatment with leronlimab as part of her therapy for breast cancer. The treating physician noted her partial paralysis was mitigated relatively quickly, which may have been causally related to the posited role of CCR5 in stroke.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, “Leronlimab’s ability to cross the blood-brain barrier potentially presents numerous opportunities for the treatment of patients suffering from diseases related to the central nervous system. Therefore, we are accelerating the filing of a Phase 2 protocol to evaluate leronlimab’s potential as a therapeutic for stroke recovery. We continue to focus our energies on our most important task of enrolling more patients in our severe-to-critical COVID-19 Phase 3 trial as quickly as possible. In addition to moving forward rapidly to complete our Biologics License Application for HIV, in multiple countries, our extensive plan includes filing a protocol and IND for Phase 2 clinical trials for both stroke and Long Haulers COVID-19 indications. We continue to strongly believe leronlimab has the potential to provide therapeutic benefit to patients suffering from a variety of diseases, and this incredible prospect drives our management team every day. CytoDyn is committed to fulfilling this obligation to patients of the world.”

About Leronlimab’s Ability to Cross BloodBrain Barrier
The blood-brain barrier (BBB) mediates the communication between the periphery and the central nervous system (CNS). The BBB separates the circulation from the brain. It is a highly selective permeable border

Can’t find a leg extension machine? Rakul Preet Singh shows an alternative in her 4 am fitness video – fitness

Making us enter the week with rejuvenated enthusiasm for fitness is Bollywood diva Rakul Preet Singh’s latest workout video. Currently in Hyderabad, the actor was seen up and sweating at 4:57 am to burn calories sans excuses.

Taking to her Instagram handle, Rakul gave health freaks a sneak peek into her intense exercise session where she showed a perfect alternative if one can’t find a leg extension machine. Nailing the exercise routine, Rakul was seen using a bench for leg extension workout in the absence of a machine.

The video featured Rakul donning a blue printed tank top teamed with a pair of black tights having sheer detailing. Pulling back her hair in a high ponytail hairstyle to that they do not mess with her exercise routine, Rakul completed the athleisure dressing with a pair of black gloves to create resistance and a pair of black lace-up trainers.

Placing her hands firmly on the floor with her legs high up on the bench, Rakul worked on her quadriceps which is the large muscles of the front of the thigh. She captioned the video, “Excuses don’t burn calories (sic)” and we cannot agree more.

 

The quads are the biggest muscle in the human body and strong quads are important for a good posture, walking and squatting. The leg extension strengthens the quadriceps while also engaging the muscles in the core, butt, hips and lower legs.

It strengthens the patellar ligament and quadriceps attachment for the knee even as they are notoriously difficult to develop or tone. Bending and straightening the leg from the knee are the two basic movements of this exercise.

Follow more stories on Facebook and Twitter

Source Article

Piers Morgan compares watching Meghan and Harry’s ‘woke’ Netflix shows to ‘having a root canal at the dentist’

PIERS Morgan has has compared watching Prince Harry and Meghan Markle’s “woke” Netflix shows as much as a painful dental procedure.

The 55-year-old Good Morning Britain star has made yet another dig at the former Royal couple, who moved to LA and are forging a joint career in TV.

Piers Morgan isn't looking forward to Meghan and Harry's new shows

4

Piers Morgan isn’t looking forward to Meghan and Harry’s new showsCredit: AFP – Getty

The pair have signed a £120million contract to make documentaries, films and even children’s shows for the streaming giant.

But Piers compared watching one of their films to a root canal – where the infected pulp and nerve is removed from the root of a tooth.

He told the Sunday Mirror: “I am looking forward to all their woke documentaries with the kind of enthusiasm I look forward to having root canal surgery at the dentist.”

With bonuses, Meghan and Harry could end up pocketing a staggering £200m in what one expert called a “massive historical deal”.

The GMB star compared tuning in to taking a trip to the dentist

4

The GMB star compared tuning in to taking a trip to the dentistCredit: Rex Features
The pair have agreed a mega-money deal to make shows for Netflix

4

The pair have agreed a mega-money deal to make shows for NetflixCredit: Reuters
Piers suggested the couple make a version of The Crown called The Frown

4

Piers suggested the couple make a version of The Crown called The FrownCredit: Getty Images – Getty

Piers has previously mocked the couple’s move into TV calling their company “Megxit Productions” and suggesting titles for shows they could make.

His ideas included a version of The Crown called The Frown, where Harry and Meghan become King and Queen.

He also suggested a reality show where Harry re-joins the Army, calling it I Don’t Want To Be A Vacuous Celebrity Any More… Get Me Out Of Here.

Piers Morgan asks Trump to re-follow him on Twitter and says if he does ‘he may win election’

Source Article

Mouse study shows how a virus may trigger diabetes

New research conducted in mice has shown how coxsackievirus B type 4 — an enterovirus, a virus transmitted through the intestines — may be able to trigger diabetes in people who have the virus.

A new study has shown a possible mechanism for triggering diabetes in people who have coxsackievirus B type 4 (CVB4), a type of enterovirus.

The research, published in the journal Cell Reports Medicine, may also be valuable in exploring whether SARS-CoV-2, the virus at the heart of the current pandemic, can trigger diabetes.

According to the Centers for Disease Control and Prevention (CDC), diabetes is an ongoing health condition that affects how a person’s body transforms food into energy.

As a person consumes food and drinks, their blood sugar increases. Their pancreas then produces the hormone insulin, which enables cells to access this blood sugar.

However, a person with diabetes may not be able to either make good use of insulin (type 2 diabetes) or produce enough of it (type 1 diabetes).

Type 2 diabetes is by far the most common form of diabetes, accounting for approximately 90–95% of all cases of diabetes in the adult population.

The American Diabetes Association consider both types of diabetes to be caused by a combination of genetic and environmental factors.

For type 1 diabetes, scientists believe that viruses are one aspect of these environmental factors.

In particular, research suggests that enteroviruses — a family of viruses that can cause a variety of diseases with “neurologic, respiratory, skin, and gastrointestinal” symptoms — may be key viral triggers for type 1 diabetes.

However, scientists are not yet sure exactly how this triggering function occurs.

In the present study, the researchers wanted to better understand how enteroviruses may trigger type 1 diabetes.

To do so, they used mice that had been grafted with human pancreatic cells with CVB4, as well as human and mouse insulin-producing cells that also had the virus.

After conducting various experiments with these infected cells, the researchers identified a complex chain of events that may account for the trigger of diabetes.

The researchers observed that CVB4 infection induced downregulation of URI, a protein that controls various cellular functions. This downregulation triggered a cascade of molecular events.

This in turn resulted in the silencing of the gene Pdx1, which governs the function of beta cells in the pancreas. These beta cells produce insulin.

As Dr. Nabil Djouder, a researcher at the Spanish National Cancer Research Center and the lead author of the study, explains, “Pdx1 silencing causes the loss of the identity and function of the beta cells, which become more like alpha cells, in charge of increasing blood glucose levels, and hence leading to hyperglycemia and subsequent diabetes, independently of any immune reactions.”

Helping to corroborate their findings, the researchers also noted that mice with diabetes that overexpressed the URI protein were more tolerant of blood sugar changes.

Finally, the researchers noted a correlation between the expression of URI, Pdx1, and viral particles in